Voice your opinion on congressional bill HR3379-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

S4796-116, HR8527-116,

House committee actions Actions

Committee
Jun. 21 2019	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral
Jun. 20 2019	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Jun. 20 2019	Introduced in House Introduced in House

House bill HR3379-116

PRICED Act

Promote the cause!

Or use this QR code